Acta Med. 2002, 45: 145-147

Antiacetylcholinesterase Activity of Cyclosporine – A Comparison of Single and Repeated Administration and Effect of 7-Methoxytacrine

Josef Herink, Gabriela Krejčová, Jiří Bajgar

Purkyně Military Medical Academy in Hradec Králové, Department of Toxicology, Hradec Králové, Czech Republic

Received September 1, 2002
Accepted November 1, 2002


1. Bajgar J, Fusek J, Skopec, F. Changes of cholinesterases in the blood and some tissues following administration of tacrin and its two derivatives to rats. Neurochem Int 1994; 24:555–8. <>
2. Borlongan CV, Stahl CE, Keep MF, Elmér E, Watanabe S. Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats. Neurosci Lett 2000; 279:73–6. <>
3. Demeule M, Laplante A, Sepehr-Araé A et al. Inhibition of P-glycoprotein by cyclosporin A analogues and metabolites. Biochem Cell Biol 1999; 77:47–58. <>
4. Ellman GL, Courtney DK, Andres V, Featherstone RMX. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmac 1961; 7:88–95. <>
5. Famiglio L, Racusen L, Fivush B, Solez K, Fisher R. Central nervous system toxicity of cyclosporine in a rat model. Transplantation 1989; 48:316–21. <>
6. Farghali H, Mašek K. Immunopharmacologic agents in the amelioration of hepatic injuries. Int J Immunopharmacol 1998; 20:125–39. <>
7. Fricker G, Fahr A. Mechanism of hepatic transport of Cyclosporin A: An explanation for its cholestatic action? Yale J Biol Med 1997; 70:379–90.
8. Gaudry-Talarmain YM, Moulian N. Cyclosporin A affects functions concerning acetylcholine release of cholinergic Torpedo synaptosomes. Europ J Pharmacol 1996; 296:341–5. <>
9. Herink J, Bajgar J, Svoboda Z, Květina J, Živný P, Palička V. Effect of acetyl-Lcarnitine on the anticholinesterase activity of 7-methoxytacrine in vivo. Voj Zdrav Listy 2001; 70:87–9.
10. Imerman B, Caruso LJ. Prolonged neuromuscular block in a patient undergoing renal transplantation. J Clin Anesthesia 2000; 13:540–4. <>
11. Jeruss J, Braun SV, Reese JC, Guillot A. Cyclosporine-induced white and gray matter central nervous system lesions in a pediatric renal transplant patient. Pediatr Transplantation 1998; 2:45–50.
12. Kmoníčková E, Kameníková L, Hynie S, Farghali H. Cyclosporin A modifies cytoplasmic calcium levels in isolated hepatocytes exposed to oxidative stress due to tert-butyl hydroperoxide. Physiol Res 2000; 49:471–4.
13. Kondo Y, Asanuma M, Iwata E, Kondo F, Miyzaki I, Ogawa N. Early treatment with cyclosporin A ameliorates the reduction of muscarinic acetylcholine receptors in gerbil hippocampus after transient forebrain ischemia. Neurochem Res 1999; 24:9–13. <>
14. Krejčová G, Herink J. Současné poznatky o cyklosporinu A. Voj Zdrav Listy 2002; 71(in press).
15. Lin MJ,Lin-Shiau SY. Enhanced spontaneous transmitter release at murine motor nerve terminals with cyclosporine. Neuropharmacol 1999; 38:195–8. <>
16. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66:807–15. <>
17. Lu YF, Tomizawa K, Moriwaki A et al. Calcineurin inhibitors, FK506 and cyclosporin A, suppress the NMDA receptor-mediated potentials and LTP, but not depotentiation in the rat hippocampus. Brain Res 1996; 729:142–6. <>
18. Luo ZD, Wang Y, Werlen G, Camp S, Chien KR, Taylor P. Calcineurin enhances acetylcholinesterase mRNA stability during C2-C12 muscle cell differentiation. Mol Pharmacology 1999; 56:886–94. <>
19. Maťha V. Cyclosporin A. Praha: Grada Publishing, 1994:160.
20. Scheinman SJ, Reinitz ER, Petro G, Schwartz RA. Cyclosporine central neurotoxicity following renal transplantation. Transplantation 1990; 49:215–6. <>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal